Friday, 19 March 13:00

Dr James Brown , University of Limerick

The title of this webinar is:

“Restraining KATs: new therapeutics and breast cancer biomarkers”.

Abstract 

“The focus of my talk, and my Oncobiology and Molecular Therapeutics Group is exploring the role of lysine acetylation in regulating genome stability, and how this can be controlled by our new targeted inhibitors as the potential next generation of therapeutics. Our fundamental research explores new roles for the lysine acetyltransferase (KAT) Tip60 dependent signalling (focusing on the DNA double strand break response). Our translational projects focus on pre-clinical validation of the in vivo mechanisms of action of our lysine acetyltransferase inhibitor (KATi) TH1834.

The secondary focus in my group is the discovery and validation of breast cancer biomarkers (proteins and miRNA), both circulating in the blood and in tumour biopsies. Our current collaborative projects in this area are utilising AI-based analysis, combined with digital pathology. Our biomarker research aims to validate markers for improved disease and patient stratification, with a focus on improving treatment choice and response prediction.”

Speaker Profile 

Dr Brown received his B.App.Sc.(Hons) through the Queensland University of Technology (Brisbane, Australia). He completed his PhD at the Queensland Institute of Medical Research (Brisbane, Australia) under Professor Martin Lavin, exploring the cellular response to genotoxic stress. He moved to NUI Galway undertaking further postdoctoral training within the Centre for Chromosome Biology before setting up his own research group in the Lambe Institute for Translational Research. He took up his current post as principal investigator and lecturer at the University of Limerick in 2019.

University of Limerick Cancer Network (ULCaN): Developing a research focused infrastructure that facilitates project design and development between multidisciplinary teams working along the ‘The Cancer Journey’

Cancer is a debilitating disease and it is a significant strain on families, health care workers and on the economy. At the University of Limerick and University Hospital Limerick, we have pockets of excellent cancer research activities scattered throughout the network. Our researchers are contributing significantly to the understanding of cancer and are integral to projects that are having real impact and influencing national and international policy. Through ULCaN, we are creating an infrastructure to facilitate academic and clinical researchers to undertake multidisciplinary research by providing a roadmap to assemble teams, illustrate mechanisms to facilitate the sharing of information and promote opportunities for project development to build capacity in UL and UHL.

The cluster and its associated activities will help propel the reputation of Health Research Institute as an Institute that can perform holistic disease research. Our overarching objective is to help patients on the Cancer Journey. Our cluster is truly multidisciplinary and consists of 4 overlapping core pillars:

(1) Patient Perspectives

(2) Clinical Trials and Interventions

(3) Basic Biomedical Science, and

(4) Development novel approaches to share information and manage data will underpin these pillars.